(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €33.62 | 4.23% | 7.15% |
| TUBIZE-FIN (TUB.BR) | €116.20 | 0.8% | 4.82% |
| SARTORIUS STED BIO (DIM.PA) | €264.30 | 0.39% | 5.31% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
4.23% Forward Dividend Yield and 7.15% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.74.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 12.27. Meaning, the purchaser of the share is investing €12.27 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.15%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.7%, now sitting on 493.25M for the twelve trailing months.
Volatility
BOIRON’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.44%, a negative 0.03%, and a positive 1.87%.
BOIRON’s highest amplitude of average volatility was 0.84% (last week), 2.18% (last month), and 1.87% (last quarter).
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 3, 2024, the estimated forward annual dividend rate is 1.35 and the estimated forward annual dividend yield is 4.23%.
Volume
Today’s last reported volume for BOIRON is 1545 which is 88.44% below its average volume of 13371.
More news about BOIRON.
2. TUBIZE-FIN (TUB.BR)
0.8% Forward Dividend Yield and 4.82% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €2.02.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 57.52. Meaning, the purchaser of the share is investing €57.52 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.82%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Apr 30, 2024, the estimated forward annual dividend rate is 0.97 and the estimated forward annual dividend yield is 0.8%.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €116.20 at 02:30 EST, below its 52-week high of €124.80 and way higher than its 52-week low of €60.80.
More news about TUBIZE-FIN.
3. SARTORIUS STED BIO (DIM.PA)
0.39% Forward Dividend Yield and 5.31% Return On Equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.31%.
Volatility
SARTORIUS STED BIO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.02%, a positive 0.47%, and a positive 2.35%.
SARTORIUS STED BIO’s highest amplitude of average volatility was 1.23% (last week), 3.07% (last month), and 2.35% (last quarter).
Sales Growth
SARTORIUS STED BIO’s sales growth is 7.9% for the ongoing quarter and 6.5% for the next.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 16.5% and 50%, respectively.
More news about SARTORIUS STED BIO.
